The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial
Abstract
BACKGROUND There is increasing interest in replacing alteplase with tenecteplase as the preferred thrombolytic treatment for patients with acute ischaemic stroke. We aimed to establish the non-inferiority of tenecteplase to alteplase for these patients. METHODS In this multicentre, prospective, open-label, blinded-endpoint, randomised controlled, non-inferiority trial, adults with an acute ischaemic stroke who were eligible for standard intravenous thrombolysis but ineligible for endovascular thrombectomy were enrolled from 53 centres in China and randomly assigned (1:1) to receive intravenous tenecteplase (0·25 mg/kg, maximum dose of 25 mg) or intravenous alteplase (0·9 mg/kg, maximum dose of 90 mg). Participants had to be able to receive treatment within 4·5 h of stroke, have a modified Rankin Scale (mRS) score of no more than 1 before enrolment, and have a National Institutes of Health Stroke Scale score of 5-25. Patients and treating clinicians were not masked to group assignment; clinicians evaluating outcomes were masked to treatment type. The primary efficacy outcome was the proportion of participants who had a mRS score of 0-1 at 90 days, assessed in the modified intention-to-treat population (all randomly assigned participants who received the allocated thrombolytic), with a non-inferiority margin of 0·937 for the risk ratio (RR). The primary safety outcome was symptomatic intracranial haemorrhage within 36 h, assessed in all participants who received study drug and had a safety assessment available. The trial is registered with ClinicalTrials.gov, NCT04797013, and has been completed. FINDINGS Between June 12, 2021, and May 29, 2022, 1430 participants were enrolled and randomly assigned to tenecteplase (n=716) or alteplase (n=714). Six patients assigned to tenecteplase and seven to alteplase did not receive study product, and five participants in the tenecteplase group and 11 in the alteplase group were lost to follow-up at 90 days. The primary outcome in the modified intention-to-treat population occurred in 439 (62%) of 705 in the tenecteplase group versus 405 (58%) of 696 in the alteplase group (RR 1·07, 95% CI 0·98-1·16). The lower limit of the RR's 95% CI was greater than the non-inferiority margin. Symptomatic intracranial haemorrhage within 36 h was observed in 15 (2%) of 711 in the tenecteplase group and 13 (2%) of 706 in the alteplase group (RR 1·18, 95% CI 0·56-2·50). Mortality within 90 days occurred in 46 (7%) individuals in the tenecteplase group versus 35 (5%) in the alteplase group (RR 1·31, 95% CI 0·86-2·01). INTERPRETATION Tenecteplase was non-inferior to alteplase in people with ischaemic stroke who were eligible for standard intravenous thrombolytic but ineligible for or refused endovascular thrombectomy. FUNDING National Science and Technology Major Project, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National Natural Science Foundation of China, and China Shijiazhuang Pharmaceutical Company Recomgen Pharmaceutical (Guangzhou).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Dávalos, A., Guidetti, D., Larrue, V., Lees, K. R., Medeghri, Z., Machnig, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804656 · Cited by 6,684
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309023291001 · Cited by 4,055
Emberson, J., Lees, K. R., Lyden, P., Blackwell, L., Albers, G., Bluhmki, E., Brott, T., Cohen, G., Davis, S., Donnan, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60584-5 · Cited by 2,737
Self-citationWahlgren, N., Ahmed, N., Dávalos, A., Ford, G. A., Grond, M., Hacke, W., Hennerici, M. G., Kaste, M., Kuelkens, S., Larrue, V., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60149-4 · Cited by 2,379
European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke
Berge, E., Whiteley, W., Audebert, H., De Marchis, G., Fonseca, A. C., Padiglioni, C., Pérez de la Ossa, N., Strbian, D., Tsivgoulis, G., & Turc, G. (2021) · European Stroke Journal · doi:10.1177/2396987321989865 · Cited by 1,355
Do Clinicians Overestimate the Severity of Intracerebral Hemorrhage?
Tilling, E. J., El Tawil, S., & Muir, K. W. (2019) · Stroke · doi:10.1161/strokeaha.118.022606 · Cited by 1,120
Van de Werf, F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)07403-6 · Cited by 885
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
Campbell, B. C. V., Mitchell, P. J., Churilov, L., Yassi, N., Kleinig, T. J., Dowling, R. J., Yan, B., Bush, S. J., Dewey, H. M., Thijs, V., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716405 · Cited by 885
Self-citationA Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke
Parsons, M., Spratt, N., Bivard, A., Campbell, B., Chung, K., Miteff, F., O'Brien, B., Bladin, C., McElduff, P., Allen, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109842 · Cited by 680
Self-citationMenon, B. K., Buck, B. H., Singh, N., Deschaintre, Y., Almekhlafi, M. A., Coutts, S. B., Thirunavukkarasu, S., Khosravani, H., Appireddy, R., Moreau, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01054-6 · Cited by 474
Self-citation
Metadata
- Authors
- Wang, Y., Li, S., Pan, Y., Li, H., Parsons, M. W., Campbell, B. C. V., Schwamm, L. H., Fisher, M., Che, F., Dai, H., Li, D., Li, R., Wang, J., Wang, Y., Zhao, X., Li, Z., Zheng, H., Xiong, Y., Meng, X., Li, R., Wang, D., Wang, Y., Chen, S., Deng, D., Zhang, H., Wang, J., Chen, H., Zhang, H., Wu, Y., Liu, H., Lu, G., Zhao, L., Zhu, R., Liu, Y., Yi, F., Gao, J., Dai, H., Hao, J., Che, F., Cai, X., Duan, Z., Yu, H., Wei, T., Tang, Y., Peng, Z., Zhang, B., Song, Y., Chen, X., Liu, Y., Liu, J., Li, D., Zhao, W., Wei, X., Xue, Q., Liu, X., Yang, Y., zhao, C., Chen, J., Sui, Y., Sheng, G., Zhang, Y., Liu, J., Zhang, L., Wang, W., Guo, Z., Li, H., Hu, R., Chen, G., Liang, Z., Chen, J., Xia, L., & Long, Z.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 401
- Issue
- 10377
- Pages
- 645-654
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4319663675
- Cited by
- 316
- References
- 23
- FWCI
- 52.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)02600-9
- The paper
- Wang, Y., Li, S., Pan, Y., Li, H., Parsons, M. W., Campbell, B. C. V., Schwamm, L. H., Fisher, M., Che, F., Dai, H., Li, D., Li, R., Wang, J., Wang, Y., Zhao, X., Li, Z., Zheng, H., Xiong, Y., Meng, X., . . . Long, Z. (2023). Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)02600-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.